Verastem Is Getting a New CEO, $250 Million, and a Shot at Another Cancer Drug

Verastem plans to raise $250 million as it prepares for late-stage testing of its experimental cancer treatment.

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。